title: Re-calculating! Navigating through the osteosarcoma treatment roadblock.
abstract: The survival rates for patients with osteosarcoma have remained almost static for the past three decades. Current standard of care therapy includes chemotherapies such as doxorubicin, cisplatin, and methotrexate along with complete surgical resection and surgery with or without ifosfamide and etoposide for relapse, though outcomes are hoped to be improved through clinical trials. Additionally, increased understanding of the genetics, signaling pathways and microenvironmental factors driving the disease have led to the identification of promising agents and potential paths towards translation of an exciting array of novel targeted therapies. Here, we review the mechanism of action of these emerging therapies and how, with clinical translation, they can potentially improve the survival rates for osteosarcoma patients in the near future.
authors.affiliation: Department of Tumor Biology, H. Lee Moffitt Cancer Research Center and Institute, 12902 Magnolia Dr. Tampa, FL, 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL, 33612, USA.
authors.forename: J
authors.initials: J
authors.lastname: McGuire
authors.affiliation: Department of Orthopaedics and Rehabilitation, Vanderbilt University, Nashville, TN, 37212, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Utset-Ward
authors.affiliation: Adolescent and Young Adult Program and Sarcoma Department, H. Lee Moffitt Cancer Research Center and Institute, 12902 Magnolia Dr. Tampa, FL, 33612, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Reed
authors.affiliation: Department of Tumor Biology, H. Lee Moffitt Cancer Research Center and Institute, 12902 Magnolia Dr. Tampa, FL, 33612, USA. Electronic address: conor.lynch@moffitt.org.
authors.forename: C C
authors.initials: CC
authors.lastname: Lynch
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000401:mortality; D015398:Signal Transduction / Q000187:drug effects; D015996:Survival Rate; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents
keywords: Bone; Clinical trials; Inhibitors; Metastasis; Microenvironment; Osteosarcoma